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Interest in patient adherence has increased in recent years, with a growing literature that shows the pervasiveness of poor adherence
to appropriately prescribed medications. However, four decades of adherence research has not resulted in uniformity in the
terminology used to describe deviations from prescribed therapies. The aim of this review was to propose a new taxonomy, in which
adherence to medications is conceptualized, based on behavioural and pharmacological science, and which will support quantifiable
parameters. A systematic literature review was performed using MEDLINE, EMBASE, CINAHL, the Cochrane Library and PsycINFO from
database inception to 1 April 2009. The objective was to identify the different conceptual approaches to adherence research.
Definitions were analyzed according to time and methodological perspectives. A taxonomic approach was subsequently derived,
evaluated and discussed with international experts. More than 10 different terms describing medication-taking behaviour were
identified through the literature review, often with differing meanings. The conceptual foundation for a new, transparent taxonomy
relies on three elements, which make a clear distinction between processes that describe actions through established routines
(‘Adherence to medications’, ‘Management of adherence’) and the discipline that studies those processes (‘Adherence-related sciences’).
‘Adherence to medications’ is the process by which patients take their medication as prescribed, further divided into three quantifiable
phases: ‘Initiation’, ‘Implementation’ and ‘Discontinuation’. In response to the proliferation of ambiguous or unquantifiable terms in the
literature on medication adherence, this research has resulted in a new conceptual foundation for a transparent taxonomy. The terms
and definitions are focused on promoting consistency and quantification in terminology and methods to aid in the conduct, analysis
and interpretation of scientific studies of medication adherence.
Introduction
Sub-optimal adherence to prescribed medicines is fre-
quently the principal obstacle to successful pharmaco-
therapy in ambulatory patients, especially when it is
unrecognized clinically, as often occurs. It is highly preva-
lent, associated with increased morbidity and mortality,
costly tomanage,and until recently a verymuch neglected
aspect of therapeutics [1–3].
However, in the past decade there has been substantial
growth in adherence research, partly owing to increasing
awareness of the size and scope of the problem, partly
because of the pervasiveness of non-adherence across all
therapeutic fields and partly because of its potentially
large contribution to the overall variance in drug
responses. Many patients do not adhere to effective treat-
ments for the preservation of life [4, 5], quality of life [6–8],
organs [9] or sight [10, 11], with direct clinical [12, 13] and
economic consequences [14, 15].
Adherence research has also been spurred by
improved methods for compiling dosing histories in
ambulatory patients, recognition of the importance of
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adherence to treatment outcomes in HIV-AIDS, increasing
sizes of study populations, and lengthening periods of
observation. However, this growth has been piecemeal,
with research contributions coming from a variety of per-
spectives or academic disciplines. A predictable conse-
quence has been an unsatisfactory taxonomic structure,
leading to conceptual confusion [16–19].
Currently a number of terms, e.g. ‘compliance’, ‘adher-
ence’, ‘persistence’, and ‘concordance’, are used to define
different aspects of the act of seeking medical attention,
acquiring prescriptions and taking medicines appro-
priately [20–37]. These terms are often used inter-
changeably, but they impose different views about the
relationship between the patient and the health care pro-
fessional [38–40]. ‘Compliance’, for instance, has been
viewed by many as having the negative connotation that
patients are subservient to prescribers [41–45]. The term
‘concordance’, introduced originally to describe the
patient–prescriber relationship, is sometimes incorrectly
used as a synonym for ‘compliance’ [46–57]. Most terms
used currently do not have a clear or direct translation
into different European languages [58]. These matters
lead to confusion and misunderstanding, and impede
comparisons of results of scientific research and imple-
mentation in practice [59, 60].
In this research we have searched the literature system-
atically, in order to identify the terms that have been used
to describe medication-taking behaviour, and have out-
lined the taxonomic evolution of the field. As a result we
have proposed a new taxonomy for medication taking
behaviour that will support relevant measurements. This
research was performed within the ABC (Ascertaining Bar-
riers to Compliance) project, which is an international col-
laboration of European research groups in the field of
adherence to medications funded by the European Com-
mission, Seventh Framework Programme.
Methods
The first step consisted of a systematic literature review
performed between January and June 2009.The objective
was to assess the terms and definitions that are commonly
used to describe adherence to medicines. We searched
MEDLINE, EMBASE, CINAHL, the Cochrane Library and Psy-
cINFO fromdatabase inception to 1April 2009 for all papers
addressing the taxonomy/terminology used to describe
deviations from prescribed drug treatment in ambulatory
patients.The main search terms used were ‘Patient compli-
ance’ and ‘Medication adherence’. Because of the problem
with translations,the searcheswere limited to papers in the
English language.Detailed search strategies specific to the
different databases are provided in Appendix 1.
Data extraction was undertaken by five independent
reviewers (JD, FD,EF,CM,PL) using a structured data collec-
tion sheet to gather data on (i) publication type, (ii) year of
publication, (iii) authors’ preferred terms for describing
deviations from prescribed treatment, (iv) authors’ pro-
posed definitions and (v) references cited in the paper. No
additional information was sought from the authors.
A descriptive synthesis of the extracted data was per-
formed and the historical development of the field was
analyzed. Based on the different conceptual approaches
identified in the literature review,we derived an initial new
taxonomic approach, which was first discussed internally
within the ABC project team in June 2009 in Aberdeen,UK.
The taxonomic approach was subsequently re-evaluated
in light of the identified papers and refined in June–August
2009.
A European consensusmeeting,attended by 80 partici-
pants from 13 different countries, was organized jointly
with the European Society for Patient Adherence, Compli-
ance and Persistence (ESPACOMP) in Bangor,Wales, UK on
10–11 September, 2009. During the meeting the draft
consensus document was presented and extensively dis-
cussed.To broaden this discussion,an interactive wiki web-
platform was opened during the last quarter of 2009.
In December 2009, a first report on the new taxonomy
was submitted to the EU Commission. In January 2010, an
ABC internal consensus meeting was held in Sion, Switzer-
land. During that meeting, the strengths and weaknesses
of the draft taxonomy were identified. From January 2010
until June 2010, the draft taxonomy was presented at dif-
ferent meetings and specific comments from experts were
collected.
A final ABC internal consensus meeting took place
in Leuven, Belgium in June 2010 for final approval of
the taxonomy/terminology, which was subsequently
presented at the 2010 ESPACOMP meeting held on 17–18
September in Lodz, Poland.
Results
Results from the literature review
Study selection Figure 1 depicts the study selection
process. Initial searching identified 3121 papers.Two thou-
sand nine hundred and seventy-five original articles were
excluded according to pre-defined exclusion criteria listed
in Figure 1, resulting in 146 papers to review. The publica-
tion types were literature reviews (n = 55), editorials/
commentaries/letters/discussions (n = 34), theoretical
papers/concept analyses (n = 21), research papers (n = 17),
books (n = 9), statistical papers (n = 4),meeting reports (n =
3), practice guidelines (n = 2) and an expert report (n = 1).
Terms identified Figure 2 illustrates the many different
terms describing deviations from prescribed treatment
that have been introduced in the literature throughout
the years. The data shown in this figure are incomplete
for the year 2009, as papers were included up to 1 April
2009. Since the pioneering research in this field, changes
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have occurred in prevailing philosophical paradigms and
related concepts [61–63] as depicted in Figure 3.
Hippocrates (400 BC) was the first to note that some
patients do not take their prescribed medicines, and that
many later complained because the treatment did not
help. In 1882, for the first time in modern medicine, Robert
Koch stipulated that noncompliant patients with tuber-
culosis were ‘vicious consumptives, careless and/or
irresponsible’ [61].
Beginning in the 1970s, groundwork on patient com-
pliance was initiated at McMaster University Medical
Centre, resulting in two workshops/symposia and a
seminal book entitled ‘Compliance with Therapeutic Regi-
mens’ by Sackett & Haynes [64]. This initial research was
triggered by the potential clinical consequences of patient
non-adherence and their impact on the results of clinical
trials. It was driven by a biomedical (pharmacometric) per-
spective that was concerned with pragmatic methods to
answer empirical questions about ambulatory patients’
deviations from prescribed medication, and focused on
the quantitative evaluation of the degree of correspon-
dence between the prescription and the ensuing imple-
mentation of the prescribed dosing regimen [65].The term
‘Patient compliance’ was introduced in 1975 as an official
Medical Subject Heading (MeSH) in the USNational Library
of Medicine [66, 67]. The term ‘pharmionics’, introduced in
1987, is defined as the discipline that studies how ambu-
latory patients use and misuse prescription drugs [68–70].
During early research, the role of patients’ views on
these matters was neglected, but a later body of research
addressed how prescriptions are generated, the patient’s
perspective in treatment choices and treatment manage-
ment in daily life [71]. In the meantime, ‘compliance’ has
been increasingly replaced by ‘adherence’ [3, 72, 73], as the
latter term has been thought to evoke more the idea of
cooperation between prescriber and patient, and less the
connotation of the patient’s passive obedience to the phy-
sician’s instructions [74–78]. The shift from ‘compliance’ to
‘adherence’ reflects a fundamental change in understand-
ing relationships between patients and practitioners
[79–81].
Itwas in the lightof this shift that the term‘concordance’
wasproposed [82,83].‘Concordance’wasfirst introducedby
a joint working group assembled by the Royal Pharmaceu-
tical Society of Great Britain in 1995.The‘concordance’con-
struct recognized the need for patients and health care
Potentially relevant papers identified
and screened for retrieval (n = 3121)
Based on title and abstract
Based on full text
Paper excluded (n = 2978):
Focus on refusal of specific medical practices or
Deviations from recommendations for diet, exercise,
lifestyle changes : 595
Taxonomy/terminology not targeted : 1113
Taxonomy/terminology not targeted : 32
Title was not in relation with medication adherence : 133
Not in the English language : 61
Multiple citations : 59
Papers retrieved for more detailed
information (n = 143)
Additional papers : 
Identified through experts : 16
Referenced in the literature : 29
Suggested through authors : 1
Potentially appropriate papers to be
included in the review based on title
and abstract (n = 189)
Papers excluded (n = 43) : 
Focus on refusal of specific medical practices or
treatment : 7
procedures other than pharmaceutical
pharmaceutical treatment : 1017
procedures other than
Deviations from recommendations for diet, exercise,
No full text available :  3
Papers ultimately included in the
review (n = 146) 
lifestyle changes  : 1
Figure 1
Flow diagram of the paper selection process
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providers to cooperate in the definition of a mutually
agreed treatment programme, acknowledging that
patients and providers may have differing views [83–91].
In 1997 the American Heart Association issued a state-
ment [92] in which adherence was defined as a behav-
ioural process, strongly influenced by the environment in
which the patient lives, including health care practices and
systems [93, 94].This statement contained the assumption
that satisfactory adherence depends on patients’ having
the knowledge,motivation, skills and resources required to
follow the recommendations of a health care professional.
In 2005, an important step was the recognition of
both the intentional and unintentional aspects of non-
adherence to medications [95–99]. Both facets need to be
addressed simultaneously to solve this important health
care problem. The term ‘medication adherence’ was intro-
duced as a MeSH term in 2009.
‘Compliance’ and ‘adherence’ share the property of
being quantifiable parameters, which detail when doses
are taken and how much drug each dose provides. ‘Con-
cordance’, ‘cooperation’, ‘agreement’ and ‘therapeutic alli-
ance’ imply a certain ‘meeting of the minds/perspectives’
of carers/caregivers and patients [100–105] regarding a
treatment plan suitable for a course of pharmacotherapy,
during which the patients and/or carers/caregivers bear
the responsibility for correct administration of the medi-
cine(s) [106–108].The definition of ‘correct’ is ambiguous in
the reviewed papers, because there are certain scientific
aspects of when and howmuch of certain drugs should be
taken that are not negotiable if the prescribed medicine is
to work satisfactorily, e.g. the low dose combined oral con-
traceptives, the effectiveness and safety of which depend
on specific doses and strict punctuality in the taking of
successive doses.
Cited references The most commonly cited text for the
definition of patient compliance is a 1976 paper by Sackett
& Haynes [64]. As illustrated in Table 1, several attempts
have been taken to adapt the original definition of patient
compliance in order to emphasize its psychological,behav-
ioural and ecological aspects. For example, the WHO defi-
nition of adherence addresses the need for patients to be
involved in treatment decisions.However, this change illus-
trates the potential confusion triggered by a conceptual
change, i.e. the implied need for prior agreement between
prescriber and patient regarding the treatment plan,
without regard to the measurement problem it generates.
That problem arises because of the need for (i) amethod to
measure the coincidence of the patient’s behaviour and
the provider’s recommendation, (ii) a method for measur-
ing agreement between the patient and care-provider,
plus (iii) means to avoid the resulting methodological
impasse by findingways to integrate these two dimension-
ally different measurements.
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Figure 2
Frequency histogram presenting the evolution over time of the main terms used among the 146 papers to describe deviations from prescribed treatments.
Adherence ( ); Compliance ( ); Persistence ( ); Concordance ( ); Pharmionics ( ); Therapeutic Alliance ( ); Persistency ( ); Patient irregularity ( );
Pharmacoadherence ( ); Other ( )
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In summary, ‘patient compliance’ and ‘medication
adherence’ have been the most widely-used terms, each
serving as indexing terms in the Index Medicus of the US
National Library of Medicine. However, the definitions of
these terms are unsatisfactory [109, 110], as they are used
interchangeably but inconsistently to define variation or
uncertainties in the linkages between seeking medical
attention, acquiring prescriptions [111], and deviating
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Figure 3
Time-line of changes in terminology for deviations from prescribed dosing regimens
Table 1
Illustration of changes and adaptations of the original definition of patient compliance over the years
Definition Authors – Year
Compliance is the extent to which the patient’s behaviour (in terms of taking medications, following diets or executing
other lifestyle changes) coincides with the clinical prescription.
Sackett & Haynes (1976) [64]
Compliance is the extent to which the patient’s behaviour coincides with the clinical prescription, regardless of how the
latter was generated.
Sackett & Haynes (1976) [64]
Compliance is the extent to which a person’s behaviour (in terms of taking medication: following diets, or executing
other lifestyle changes) coincides with medical or health advice.
Haynes et al. (1979) [143]
Compliance is the extent to which an individual chooses behaviours that coincide with a clinical prescription, the
regimen must be consensual, that is, achieved through negotiations between the health professional and the patient.
Dracup & Meleis (1982) [144]
Adherence is the degree to which a patient follows the instructions, proscriptions, and prescriptions of his or her
doctor.
Meichenbaum & Turk (1987) [145]
Adherence is the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle
changes – corresponds with agreed recommendations from a health care provider.
World Health Organization; (2003) [3]
Adherence is the extent to which a patient participates in a treatment regimen after he or she agrees to that regimen. Balkrishnan (2005) [146]
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from the administration of medicines as prescribed
[112–114].
Because of the breadth of the topic and the multiple
behaviours that are subsumed under it,no single term (e.g.
‘adherence’) or definitionmeets all needs of the field [115–
128]. There is thus a clear need to create an agreed set of
rules [129],within which future activities can fit, to provide
concise and adequate definitions and an associated con-
ceptual framework that could serve the needs of both
clinical research and medical practice [129, 130].
Results from the European Consensus Meeting
At the 13th annual ESPACOMP meeting in September 2009
at Bangor University,Wales, UK, the ABC consortium coor-
dinated the ‘European consensus meeting on the tax-
onomy and terminology of patient compliance’.A proposal
for a sound taxonomy/terminology in the field of patient
adherence was introduced by Dr Bernard Vrijens (ABC
work-package leader) who presented the research work
that had been performed within the ABC project and pro-
posed a new taxonomy.
Themeetingwas attended by 80 participants fromAus-
tralia, Belgium, Denmark, France, Germany, Italy, the Neth-
erlands, Norway, Poland, Portugal, Switzerland, the United
Kingdom and the United States.
Dr Jeffrey Aronson (University of Oxford, UK) chaired
the session and supervised the interactive discussion with
the participants. Dr Lars Osterberg (Stanford University
School of Medicine, Stanford, California, USA) and Dr
Robert Vander Stichele (University of Ghent, Belgium) par-
ticipated in a panel discussion.Discussions were recorded.
During the meeting, 40 attendees participated in the elec-
tronic voting on a consensus on taxonomy in the field of
deviations from prescribed treatment.
Forty-six % of the audience indicated that they had
been involved in matters relating to adherence for 2–5
years, 57% were researchers and 25% were health care
professionals. Forty-eight % were from academia, 15%
from pharmaceutical companies and 8% from health ser-
vices. Twenty-five % were clinically qualified as medical
doctors, 30% as pharmacists, and 5% as nurses.
Most (60%) of the participants declared that the term
‘Medication adherence’ was their preferred term for
describing patients’ medicines taking behaviour vs. 25%
who voted for the term ‘Patient compliance’. When asked
for the designation of a certain level of compliance (‘What
does it mean to you to read that a clinical study reported a
compliance level of 90%?’), the opinions were inconsistent.
This finding suggests that some of the widely used terms
have quite different meanings to researchers working
within different scientific and medical fields. These differ-
ences are one of the reasons why it is important to forge a
uniform taxonomy that supports quantitative, pharmaco-
metrically sound assessment. However 95% of the audi-
ence did distinguish between how long a treatment is
pursued from how well a dosing regimen is implemented.
Fifty-three % of the participants considered that the terms
adherence and compliance might be used interchange-
ably but considered that the term ‘concordance’ has a dis-
tinctly different meaning from either ‘adherence’ or
‘compliance’. A majority (61%) of the voters preferred the
term ‘discontinuation’ to describe patients’ premature
ending of prescribed therapy while 37% preferred the
term ‘non-persistence’. Participants were then asked
whether they agreed with the proposed taxonomy previ-
ously presented by Dr Bernard Vrijens. A majority (77%)
agreed with the proposed taxonomy and 72% also agreed
with the proposed terminology; 15% were not sure about
the proposal. If a European consensus on terminology
were to be produced,49%of the participants said that they
would use it irrespective of whether they agreed with the
content and 46% said that they would use it sometimes.
To broaden this discussion to a larger public it was
decided to use a wiki-type collaborative web-platform. An
announcement of this website has been sent to the
members of the ESPACOMPmailing list (n = 1321) to invite
them to sign up on this platform and to share some of their
thoughts and opinions on this important topic with the
wider public who are interested in patient adherence. The
revised taxonomy originally posted on the wiki web-
platform was well attended with up to 125 visits/day but
few comments were posted.
A proposed taxonomy/terminology
The new conceptual foundation for a transparent tax-
onomy relies on three elements, which make a clear dis-
tinction between processes that describe actions through
established routines (‘Adherence to medications’,‘Manage-
ment of adherence’) and the disciplines which study those
processes (‘Adherence-related sciences’). The proposed
taxonomy is described below and the corresponding
terms and definitions are summarized in Table 2.
Adherence to medications The first element is named
adherence to medications, the process by which patients
take their medications as prescribed. Adherence has three
components: initiation, implementation, and discontinua-
tion (see Figure 4). The process starts with initiation of the
treatment, when the patient takes the first dose of a pre-
scribed medication.The process continues with the imple-
mentation of the dosing regimen, defined as the extent to
which a patient’s actual dosing corresponds to the pre-
scribed dosing regimen, from initiation until the last dose is
taken.Discontinuation marks the end of therapy,when the
next dose to be taken is omitted and no more doses are
taken thereafter. Persistence is the length of time between
initiation and the last dose, which immediately precedes
discontinuation.
Non-adherence to medications can thus occur in
the following situations or combinations thereof: late or
non-initiation of the prescribed treatment, sub-optimal
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implementation of the dosing regimen or early discontinu-
ation of the treatment.
Management of adherence The second element of the
taxonomy is named management of adherence, and is the
process of monitoring and supporting patients’ adher-
ence to medications by health care systems, providers,
patients, and their social networks. The objective of man-
agement of adherence is to achieve the best use by
patients, of appropriately prescribed medicines, in order
to maximize the potential for benefit and minimize the
risk of harm.
Note that the Index Medicus includes the indexing
term ‘medication adherence’, using ‘medication’ as a noun
modifier.We prefer the term ‘adherence to medication’, but
the two terms can be used interchangeably. Following the
same argument, ‘Adherence management’ can be used as
an alternative to ‘Management of adherence’.
Adherence-related sciences The third element is named
adherence-related sciences. This element includes the
disciplines that seek understanding of the causes or
consequences of differences between the prescribed
(i.e. intended) and actual exposures to medicines. The
complexity of this field, as well as its richness, results from
the fact that it operates across the boundaries between
many disciplines, including, but not limited to medicine,
pharmacy,nursing,behavioural science,sociology,pharma-
cometrics, biostatistics and health economics.
Quantification of adherence to medications
An apt quantification of adherence to medications
constitutes the basis for adherence-related sciences [131].
In turn, this quantification informs the process of manag-
ing adherence, the aim of which is to help patients
to take appropriately prescribed drug dosing regimens.
These regimens depend on scientifically sound regulatory
Table 2
Summary of the taxonomy and definitions
Taxonomy Definition
Adherence to medications The process by which patients take their medications as prescribed, composed of initiation, implementation and discontinuation.
Initiation occurs when the patient takes the first dose of a prescribed medication.
Discontinuation occurs when the patient stops taking the prescribed medication, for whatever reason(s).
Implementation is the extent to which a patient’s actual dosing corresponds to the prescribed dosing regimen, from initiation until the last
dose.
Persistence is the length of time between initiation and the last dose, which immediately precedes discontinuation.
Management of adherence The process of monitoring and supporting patients’ adherence to medications by health care systems, providers, patients, and their social
networks.
Adherence-related sciences The disciplines that seek understanding of the causes or consequences of differences between prescribed (i.e. intended) and actual
exposures to medicines.
Patient
Family and
Carers
Providers and
Prescribers
Community and Institutions
Health care/Prescribing policy Management of adherence
Adherence to medications
Persistence Non-persistence
Initiation Discontinuation
First prescription End of prescribingFirst dose Last dose
Time
Implementation
Figure 4
Illustration of the process of adherence to medication (light blue) and the process of management of adherence (dark blue)
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labelling decisions, tempered by informed practices
of prescribers, and guided by evolving principles of
individualized prescribing as well as the support of
patients in the daily management of their medication
regimens. The ultimate goal is optimal pharmacothe-
rapy and its implicit association with optimal clinical
outcomes.
Pharmionics is an adherence-related science concerned
with the quantitative assessment of the three measurable
components of adherence to medications (initiation, imple-
mentation, and discontinuation), and their respective con-
tributions toward the effects of medicines. Pharmionics is
thus an adherence-related science that constitutes the link
to the biomedical field of pharmacometrics as a natural
input to pharmacokinetic and pharmacodynamic models
for quantitative analysis and projection of the conse-
quences of correct vs. incorrect dosing, and the effects of
specific errors [70].
Initiation and discontinuation of treatment are inher-
ently discontinuous actions, whereas implementation of
the dosing regimen is continuous. This difference pre-
cludes a single, quantitatively useful parameter to cover all
three.For example, the three patients illustrated in Figure 5
all took 75% of their prescribed twice daily doses over a
period of 3 months. However, the electronically compiled
drug dosing history data reveal major differences in the
dynamics of the three components of adherence to medi-
cations over time,which can reveal different causes and/or
consequences.
Initiation is often reported as the time from prescrip-
tion until first dose is taken. It is thus a time-to-event vari-
able with a well-defined time origin (prescription) and an
end-point which is the first dose taken. We note that the
end-point will not be observed for those patients who
never take the first dose within the studied period; in that
case the end-point is censored.
Persistence is the time from initiation until discontinua-
tion. It is also a time-to-event variable with a well defined
time origin (initiation) and an end-point which is the time
of treatment discontinuation. The end-point will be cen-
sored if the end-point is not observed during the studied
period.
Both variables are thus time-to-event data and should
be analyzed and interpreted using standard survival
analysis. Kaplan-Meier curves, median persistence or pro-
portion of persistent patients at a well defined time point
are the most frequent representations used.We note that
in clinical studies, patients sign an informed consent
document, and typically the first dose is administered
on site. Therefore, it is often assumed that initia-
tion is implicit for all included patients. In that case,
persistence is defined as the time from inclusion until
discontinuation.
The quantification of implementation requires the com-
parison of two time-series: the prescribed drug dosing
regimen and the patient’s drug dosing history. Its
estimation can range from a single summary statistic to a
more longitudinal comparison.
The most frequent summary statistics for quantifying,
within a patient, the implementation of a dosing regimen,
over a defined interval of time, are:
1 the proportion of prescribed drug taken;
2 the proportion of days with the correct number of doses
taken;
3 the proportion of doses taken on time, in relation to a
prescription-defined time interval between successive
doses;
4 the distribution of inter-dose intervals;
5 the number of drug holidays;
6 the longest interval between two doses.
However, summary statistics that are estimated over an
aggregate period of time have limitations, especially when
one wants to depict trends in the implementation of the
dosing regimen over time. It is also important to note that
some sparse measures of adherence which provide only
aggregate estimate over a defined period of time (e.g.
counting returned tablets) do not allow one to identify
precisely the discontinuation time. Thus, summary statis-
tics based on sparse measurement methods often mix the
different elements of adherence to medications and can
be very confusing.
More longitudinal comparisons which make clear dis-
tinctions between initiation, implementation, and discon-
tinuation have been proposed, as illustrated previously
using a large database of electronically compiled drug
dosing histories among patients with hypertension
[132].
Operational definitions for the implementation of a
dosing regimen should be drug- and disease-specific.Clini-
cally relevant definitions need to be developed, indicating
which deviation from the prescribed medication regimen
is sufficient to influence adversely the regimen’s intended
effect [133–135]. Further discussions on operational defi-
nitions are beyond our scope and have to do with the
intricacies of time series analyses. However, the proposed
taxonomy forms the cornerstone for concise adherence
measurement and facilitates a smooth transition from con-
ceptual to operational definitions.
Discussion
Despite four decades of adherence research, there is still
no uniformity in the terminology used to describe devia-
tion from prescribed regimens. Through its historical
development, this field of research has operated across
areas bounded by biomedical, ecological and behavioral
perspectives, the respective concepts of which are cat-
egorically dissimilar [136]. This dissimilarity has resulted
in the generation of a number of concepts and terms
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Figure 5
Examples of electronically compiled drug dosing history data in three patients for whom a twice daily dosing regimenwas prescribed.Blue dots indicate the
dates and times of drug intake. Grey bars indicate missed doses. (A) Patient with late initiation but good implementation. (B) Patient with suboptimal
implementation (missed single and consecutive doses, large variability in timing of drug intakes). (C) Patient with excellent implementation but short
persistence (early discontinuation)
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embedded in these different disciplines, making the
logical or conceptual relations between them problematic
[137]. The conceptual definitions for terms vary, and partly
overlap, resulting in conceptual confusion, which adds to
methodological weakness in the field. This problem is
further compounded by a lack of congruence between
conceptual definitions, operational definitions and mea-
surements [20, 138–142].
Because of the breadth of the topic, the multiplicity of
behaviours it subsumes and their various physical dimen-
sions, one cannot use a single term and definition to meet
all needs of the field. There is, however, a clear need to
create a set of rules, agreed upon, within which future
activities should fit, if all are committed to fulfilment of the
need for clear, concise and adequate definitions and an
associated conceptual framework, within which work can
continue. New methods and new research findings may
later force a fine tuning or even a reshaping of the field’s
taxonomy.Careful attention to themetrics for, and physical
dimensions of, proposed terms or parameters is one of the
pillars on which a sound taxonomy should rest.
Previous initiatives to standardize the taxonomy of
adherence to medications were identified through the lit-
erature review. The most recent one is the attempt by the
International Society for Pharmacoeconomics and Out-
comes Research, but their definitions were driven by a
measurement method led by refill data, which delivers
only a sparse view of adherence. Our approach has inte-
grated findings from different initiatives while remaining
independent of any measurement method.
In the literature review, we have identified more than
10 different terms closely linked to the topic at hand. The
proposed taxonomy is not intended to replace all of those
terms, but each should find a place in the new taxonomic
approach. For example, ‘concordance’ and ‘therapeutic alli-
ance’ are elements of the management of the adherence
process while ‘pharmionics’ is an adherence related
science. The main remaining controversy is between the
first term introduced,‘patient compliance’ and the increas-
ingly used one ‘medication adherence’. In our view, patient
compliance is synonymous with medication adherence.
However, given the widely perceived, negative connota-
tion of ‘(non-) compliance’, and its multiple uses (e.g. com-
pliance with drug regulations, compliance with good
clinical practice, compliance with good manufacturing
practice, etc.) in many different medical and peri-medical
contexts, its use should fade out over time.
The main limitation of this work is associated with the
development of the taxonomy based on English language
literature only.This problem has been identified very early
on in the process towards a unified taxonomy. During the
European consensus meetings, issues regarding transla-
tion into German, French, Polish and Dutch have been dis-
cussed. Translation remains an important step for medical
practice and teaching in the different countries. It is
however important to have a set-up a sound taxonomy in
the English language and translation will be the topic of
further work in this field.
In response to the proliferation of sometimes ambigu-
ous terms in the literature on adherence to medications,
this research has resulted in a new conceptual foundation,
in which we have proposed a transparent taxonomy. It
should provide researchers and clinicians with a common
language for describing different experimental investiga-
tions.We hope that the proffered taxonomy will stimulate
discussion, informed by shared concepts, methods and
research findings.The terms and definitions are focused on
promoting consistency in taxonomy and methods, to aid
in the conduct, analysis and interpretation of scientific
studies of adherence to medications. The adoption of
these terms and definitions will also help to standardize
the medical literature and therefore facilitate health policy
decisions based on consistent evidence.
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Appendix 1
Specific search combinations used
in each database
1MEDLINE via Pubmed
(‘Patient compliance’ [Majr] OR ‘Treatment Refusal’ [Majr])
AND (‘Classification ‘[Subheading] OR ‘Terminology as
Topic’ [MeSH] OR ‘Concept Formation’ [MeSH] OR ‘Vocabu-
lary, Controlled’ [MeSH] OR ‘primary adherence’ [All Fields]
OR ‘primary non-adherence’ [All Fields] OR ‘readiness’ [All
Fields] OR ‘pharmionics’ [All Fields] OR ‘treatment accep-
tance’ [All Fields] OR ‘concordance’ [All Fields] OR ‘defini-
tion’ [All Fields] OR ‘taxonomy’ [All Fields] OR ‘terminology’
[All Fields] OR ‘persistence’ [All Fields] OR ‘medica-
tion possession ratio’ [All Fields] OR ‘meta-analysis’ [All
Fields])
2 EMBASE
(‘Patient compliance/exp/mj) AND (‘Primary compliance
OR ‘Primary non-compliance’OR ‘Readiness’OR ‘Pharmion-
ics’ OR ‘Treatment acceptance’ OR ‘Concordance’ OR
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‘Persistence’ OR ‘Meta-analysis’/exp OR ‘Definition’ OR
‘Taxonomy’/exp OR ‘Terminology’/exp OR ‘Concept’) AND
[EMBASE]/lim
3 CINAHL
(‘Adherence’ OR ‘Compliance’ OR ‘Persistence’ OR ‘Concor-
dance’ OR ‘Nonadherence’ OR ‘Non-adherence’ OR ‘Non-
compliance’ OR ‘Non-compliance’) AND (’Terminology’ OR
‘Classification’ OR ‘Taxonomy’ OR ‘Definition’)
4 The Cochrane Library
(‘Patient compliance’ [MeSH term] AND [‘Primary compli-
ance’[topic] OR‘Primary non-compliance’[topic] OR‘Readi-
ness’ [topic] OR ‘Pharmionics’ [topic] OR ‘Treatment
acceptance’ [topic] OR ‘Meta-analysis’ [topic] OR ‘Concor-
dance’ [topic] OR ‘Definition’ [topic] OR ‘Taxonomy’ [topic]
OR ‘Concept’ [topic] OR ‘Persistence’ [topic] OR ‘Medication
possession ratio’ [topic])
5 PsycINFO
(‘Compliance’ OR ‘Adherence’ OR ‘Concordance’ OR ‘Persis-
tence’ OR ‘Noncompliance’ OR ‘Non-Compliance’ OR ‘Non-
adherence’ OR ‘Non-adherence’) AND (‘Classification’ OR
‘Taxonomy’ OR ‘Definition’ OR ‘Terminology’)
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